VC
PCVX icon

Vivo Capital’s Vaxcyte PCVX Stock Holding History

Vivo Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-579,508
Closed -$21.7M – 51
2023
Q1 		$21.7M Hold
579,508
– – 1.51% 11
2022
Q4 		$27.8M Buy
579,508
+175,000
+43% +$6.87M 3.2% 11
2022
Q3 		$9.71M Buy
+404,508
New +$10.3M 1.07% 25

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital's PCVX Position: Q2 2023 in Review

Vivo Capital sold out of Vaxcyte (PCVX) in Q2 2023, closing a stake of 579,508 shares — an estimated $21.7M sold.

Vivo Capital first reported a position in PCVX in Q3 2022 and held it in 3 quarters. The position peaked at $27.8M in Q4 2022. 197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

  • Vivo Capital reported no remaining Vaxcyte position as of Q2 2023 after selling out during the quarter.
  • Vivo Capital sold 579,508 Vaxcyte shares in Q2 2023, an estimated $21.7M.
  • Vivo Capital first reported a position in Vaxcyte in Q3 2022 and held it in 3 quarters.
  • Vivo Capital's Vaxcyte position peaked at $27.8M in Q4 2022.
  • 197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on Vivo Capital's 13F filing for Q2 2023, filed 14 Aug 2023.